Study backs pneumatic compression method:
This article was originally published in Clinica
The first prospective study to evaluate intermittent pneumatic compression (IPC) as an adjunctive treatment for breast cancer-associated lymphedoema (fluid accumulation) has found it to be safe and effective. The study, conducted by researchers at the Stanford University School of Medicine, California, assessed the technique in 27 patients with lymphedoema as a consequence of surgery and radiation to treat breast cancer. Used alongside other, established decongestive lymphatic therapy, IPC provides an enhancement of patients' therapeutic response, say the researchers, whose findings appear in Cancer (December 1).
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.